Merus NV Form 4 insider transactions

Genmab A/S has finalized its acquisition of Merus N.V., converting all remaining minority shares into cash and delisting the company.

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. to over 72.8 million common shares following recent acquisitions as part of a tender offer.

Genmab A/S, through its subsidiary, has increased its beneficial ownership in Merus N.V. to over 94% following a tender offer and subsequent share acquisitions.

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. by acquiring additional common shares at $97.00 per share following a tender offer.

Merus N.V.'s Chief Financial Officer, Gregory D. Perry, disposed of all his share options on December 12, 2025, as part of Genmab's tender offer to acquire the company for $97.00 per share.

Merus N.V. director Anand Mehra disposed of all share options following Genmab's tender offer at $97.00 per share.

Merus N.V. director Len Kanavy's stock options were canceled for cash following Genmab's tender offer at $97.00 per share.

Merus N.V. director Jason Haddock's share options were cancelled for cash following Genmab's successful tender offer at $97.00 per share.

Merus N.V.'s COO and GC, Peter B. Silverman, disposed of all his share options for cash as part of Genmab's tender offer for Merus shares at $97.00 per share.

Merus N.V.'s Chief Medical Officer, Fabian Zohren, cashed out all his share options following Genmab's successful tender offer for Merus shares at $97.00 per share.

Merus N.V.'s President and CEO, Sven Ante Lundberg, disposed of all his common shares and cancelled all share options as part of Genmab's $97.00 per share tender offer.

Merus N.V. Director Paolo Pucci's stock options were cancelled and cashed out following Genmab's tender offer for Merus shares at $97.00 per share.

Merus N.V.'s VP Controller, Harry Shuman, disposed of all his common shares and cancelled all his share options as part of Genmab's tender offer at $97.00 per share.

Merus N.V. Director Victor Sandor received cash for his share options following Genmab's tender offer at $97.00 per share.

Merus N.V. Director Mark T. Iwicki disposed of all his common shares and cancelled all share options as part of Genmab's tender offer at $97.00 per share.

Merus N.V. director Maxine Gowen's share options were cancelled for cash following Genmab's successful tender offer at $97.00 per share.

Merus N.V.'s VP Controller, Harry Shuman, exercised options and sold 1,700 common shares for $96.1 per share, while also receiving a new option grant.

Merus N.V.'s President and CEO, Sven Ante Lundberg, reported gifting common shares to various family and annuity trusts.

Merus N.V.'s VP Controller, Harry Shuman, exercised multiple stock options and subsequently sold a portion of his common shares.

Merus N.V.'s Chief Operating Officer and General Counsel, Peter B. Silverman, exercised 25,000 stock options and simultaneously sold the acquired common shares at a significant profit, pursuant to a Rule 10b5-1 trading plan.

Merus N.V.'s Chief Operating Officer and General Counsel, Peter B. Silverman, executed pre-planned transactions, exercising stock options and subsequently selling common shares for a significant gain.

Peter B. Silverman, Chief Operating Officer and General Counsel of Merus N.V., completed a pre-arranged transaction involving the exercise of stock options and the subsequent sale of common shares.

Merus N.V. Director Len Kanavy reported the acquisition of 13,193 share options with an exercise price of $41.6, vesting over one year starting May 22, 2025.

Merus N.V. Director Paolo Pucci has been granted 13,193 stock options with an exercise price of $41.60, aligning his interests with shareholder value.

Merus N.V. Director Victor Sandor was granted 13,193 share options with an exercise price of $41.60, vesting over one year starting May 22, 2025.

Merus N.V. Director Jason Haddock has acquired 13,193 share options with an exercise price of $41.6, aligning his interests with the company's long-term performance.

Merus N.V. Director Maxine Gowen has been granted 13,193 stock options with an exercise price of $41.60, vesting over one year.

Merus N.V. Director Anand Mehra has been granted 13,193 stock options with an exercise price of $41.60, vesting over one year starting May 22, 2025.

Merus N.V. Director Mark T. Iwicki was granted 13,193 share options with an exercise price of $41.60, vesting over a one-year period.

Merus N.V.'s CEO, Sven Ante Lundberg, executed stock options on April 17, 2025, acquiring shares at prices of $12.54 and $13.52.